A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.

Trial Profile

A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs CV 8102 (Primary) ; HepaVac 101 (Primary) ; Cyclophosphamide
  • Indications Liver cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Most Recent Events

    • 20 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 15 Aug 2017.
    • 23 Apr 2017 According to trial design presented at the International Liver Congress 2017, patients enrolled from Tubingen (Germany) are invited to participate in an extension study of actively personalized vaccine (APVAC) plus CV8102.
    • 23 Apr 2017 Trial design presented at The International Liver Congress 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top